2023年5月15日，公司召开2022年年度股东大会，审议并通过了《关于2022年度利润分配及资本公积转 增股本预案的议案》，以2022年12月31日的总股本56,000.00万股为基数，向全体股东每10股派发现金红 利人民币2.8元(含税)，共计派发现金红利人民币15,680.00万元；同时，以资本公积向全体股东每10股转 增5股，转增股本前公司总股本为56,000.00万股，转增股本后公司总股本为84,000.00万股。剩余未分配 利润全部结转以后年度分配。公司2022年度利润分配及资本公积转增股本已于2023年7月11日实施完 毕，公司股份总数由56,000.00万股增加至84,000.00万股。 2023年11月7日，公司首次公开发行前已发行股份部分解除限售，解除限售股份数量为238,830,000股， 占公司总股本的比例为28.4321%。 截至公告披露日，公司总股本为84,000.00万股，其中有限售条件流通股数量为511,171,125股，占公司总 股本的比例为60.8537%；无限售条件流通股数量328,828,875股，占公司总股本的比例为39.1463%。 本次解除限售的股份为公司首次公开 ...

证券日报网讯华厦眼科（301267）11月6日在互动平台回答投资者提问时表示，近年来，公司积极举办 及参与国内外眼科学术交流活动，共同推进我国眼科临床诊疗技术、教学与科学研究发展。目前，公司 刘祖国教授、吴国基教授、潘美华教授等多位专家担任海峡两岸医药卫生交流协会眼科学专委会主任委 员、委员。未来，公司也将积极发挥区位优势，推动海峡两岸眼科行业的交流与合作，为海峡两岸眼科 行业融合发展贡献力量。 ...

评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 4,027 | 4,192 | 4,466 | 4,866 | | 同比增速(%) | 0.3% | 4.1% | 6.5% | 8.9% | | 归母净利润(百万) | 429 | 442 | 484 | 549 | | 同比增速(%) | -35.6% | 3.2% | 9.4% | 13.5% | | 每股盈利(元) | 0.51 | 0.53 | 0.58 | 0.65 | | 市盈率(倍) | 38 | 37 | 34 | 30 | | 市净率(倍) | 2.8 | 2.7 | 2.6 | 2.4 | 证 券 研 究 报 告 华厦眼科（301267）2025 年三季报点评 推荐（维持） 业绩短期承压，静待消费医疗复苏 目标价：23.05 元 事项： ❖ 公司发布 2025 年三季报，报告期内实现营收 32.72 亿元（+2.83%），归母净利 润 4.34 亿元（+3.0 ...

（编辑 任世碧） 证券日报网讯 11月5日晚间，华厦眼科发布关于首次公开发行前已发行股份解除限售并上市流通的提示 性公告称，本次解除限售的股份为公司首次公开发行前已发行的股份。本次解除限售的股东户数为2 户，解除限售股份数量共计511，170，000股，占公司总股本的比例为60.8536%，限售期为自公司首次 公开发行股票上市之日起36个月。本次解除限售股份的上市流通日期为2025年11月7日（星期五）。 ...

中国国际金融股份有限公司 关于华厦眼科医院集团股份有限公司 首次公开发行前已发行股份解除限售 并上市流通的核查意见 中国国际金融股份有限公司（以下简称"中金公司"、"保荐机构"）作为华厦眼科医 院集团股份有限公司（以下简称"华厦眼科"或"公司"）首次公开发行股票并在创业板上 市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》 以及《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等 相关法律、法规和规范性文件的规定，对华厦眼科首次公开发行前已发行股份解除限售 并上市流通的事项进行了审慎核查，具体情况如下： 一、首次公开发行股票和股本情况 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次公开发 行股票注册的批复》（证监许可〔2022〕2085 号）同意，华厦眼科医院集团股份有限公 司首次公开发行人民币普通股（A 股）股票 6,000.00 万股，并于 2022 年 11 月 7 日在深 圳证券交易所创业板上市交易。 首次公开发行股票完成后公司总股本为 56,00 ...

华厦眼科医院集团股份有限公司 关于首次公开发行前已发行股份解除限售 并上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为华厦眼科医院集团股份有限公司（以下简称"公 司"）首次公开发行前已发行的股份。 2、本次解除限售的股东户数为 2 户，解除限售股份数量共计 511,170,000 股， 占公司总股本的比例为 60.8536%，限售期为自公司首次公开发行股票上市之日 起 36 个月。 3、本次解除限售股份的上市流通日为 2025 年 11 月 7 日（星期五）。 一、首次公开发行股票和股本情况 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕2085 号）同意，华厦眼科医院 集团股份有限公司首次公开发行人民币普通股（A 股）股票 6,000.00 万股，并于 2022 年 11 月 7 日在深圳证券交易所创业板上市交易。 证券代码：301267 证券简称：华厦眼科 公告编号：2025-034 首次公开发行股票完成后公司总股本为 56,000 ...

Core Points - In November 2025, a total of 124 companies in the A-share market will have their restricted shares unlocked, amounting to approximately 8.952 billion shares with a total market value of 160.677 billion yuan, representing a month-on-month decrease of about 26.45% and a year-on-year decrease of about 44.64% [1][8] Company Summaries - Ruijie Networks has the largest unlock scale, with 700 million shares set to be released on November 20, valued at approximately 52.78 billion yuan, accounting for 88% of its total share capital [3][4] - Innovation New Materials will have 2.287 billion restricted shares unlocked on November 17, with a market value of about 10.222 billion yuan, involving shareholders such as Shandong Innovation Group and Beijing Hualian Group [6][8] - Huaxia Eye Hospital ranks third in unlock scale, with 511.7 million shares, representing 60.85% of its total share capital, valued at approximately 9.814 billion yuan [6][8] Industry Insights - The telecommunications, pharmaceutical, and electronics industries have the highest unlock market values, with Ruijie Networks leading in telecommunications, while Huaxia Eye Hospital and New Nobel are notable in the pharmaceutical sector [8][10] - In total, seven companies will celebrate their listing anniversary in November, with a combined unlock volume of approximately 390 million shares and a market value of about 12.262 billion yuan [10]

Core Viewpoint - In November 2025, a total of 124 companies in the A-share market will face the unlocking of restricted shares, amounting to approximately 8.952 billion shares with a total market value of 160.677 billion yuan, reflecting a month-on-month decrease of about 26.45% and a year-on-year decrease of about 44.64% [1][2]. Group 1: Unlocking Scale and Key Companies - The largest unlocking scale is attributed to Ruijie Networks, with a market value exceeding 50 billion yuan [1][3]. - The top three companies by unlocking scale are Ruijie Networks, Innovation New Materials, and Huaxia Eye Hospital [3][10]. - Ruijie Networks will have 700 million shares unlocked on November 20, with a market value of approximately 52.78 billion yuan, accounting for 88% of its total share capital [3][4]. Group 2: Industry Distribution - The industries with the highest unlocking market values are telecommunications, biomedicine, and electronics [10]. - In the telecommunications sector, Ruijie Networks significantly contributes to the unlocking scale, while in biomedicine, Huaxia Eye Hospital, New Nobel, and New World lead in unlocking market value [10]. Group 3: Anniversary Unlocking - Seven companies will have 39 million restricted shares unlocked in November, with a total market value of 12.262 billion yuan, including companies like Juxing Technology and Jintian Titanium Industry [1][9]. - Juxing Technology has the largest anniversary unlocking scale at approximately 3.307 billion yuan, followed by Jintian Titanium Industry and Wanyuantong with 3.195 billion yuan and 3.011 billion yuan, respectively [14].

Group 1 - The core issue is that Qingyue Technology (688496) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false financial reporting, which could lead to a forced delisting if found guilty [1][2] - The company reported a total revenue of 476 million yuan for the third quarter of 2025, a year-on-year decrease of 13.64%, and a net profit attributable to shareholders of -43.35 million yuan, an increase of 11.3% year-on-year [1] - The stock closed at 8.94 yuan per share, with a market capitalization of 4.023 billion yuan [1] Group 2 - Next week, 30 stocks will face a total unlock market value of 20.322 billion yuan, with Huaxia Eye Hospital having the largest unlock value of 9.993 billion yuan [4][5] - The highest unlock ratio is for Huaxia Eye Hospital at 60.85%, followed by several other companies with significant unlock ratios [6] - The average stock price of the 30 stocks facing unlock has decreased by 1.89% since October, with some stocks like Transsion Holdings experiencing a significant drop of 19% [9]

Core Viewpoint - Next week, 30 stocks will have their restrictions lifted, with a total market value of 20.322 billion yuan based on the latest closing prices [1] Group 1: Stock Unlocking Details - Huaxia Eye Hospital will have 511 million shares available for trading, primarily consisting of original shareholders' restricted shares, with a market value of 9.993 billion yuan, the highest among the stocks [1] - Yunding Technology follows with 153 million shares to be unlocked, mainly from the placement of shares to targeted investors, with a market value of 1.74 billion yuan [1] Group 2: Unlocking Ratios - Huaxia Eye Hospital has the highest unlocking ratio at 60.85% [1] - Other companies with significant unlocking ratios include Hongbo Pharmaceutical, Naike Equipment, Yunding Technology, Ruina Intelligent, and Gangdi Technology [1]